Goldman Sachs’s Forte Biosciences FBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $853K | Sell |
40,160
-13,313
| -25% | -$316K | ﹤0.01% | 5353 |
|
|
2026
Q1 | $1.38M | Sell |
53,473
-14,550
| -21% | -$419K | ﹤0.01% | 4852 |
|
|
2025
Q4 | $1.85M | Buy |
+68,023
| New | +$1.19M | ﹤0.01% | 4658 |
|
|
2024
Q3 | – | Sell |
-831
| Closed | -$11.2K | – | 5894 |
|
|
2024
Q2 | $11.2K | Hold |
831
| – | – | ﹤0.01% | 5540 |
|
|
2024
Q1 | $14.5K | Buy |
831
+1
| +0.1% | +$17 | ﹤0.01% | 5416 |
|
|
2023
Q4 | $17K | Sell |
830
-520
| -39% | -$7.26K | ﹤0.01% | 5453 |
|
|
2023
Q3 | $22.3K | Buy |
1,350
+517
| +62% | +$11.5K | ﹤0.01% | 5346 |
|
|
2023
Q2 | $21.7K | Buy |
833
+8
| +1% | +$208 | ﹤0.01% | 5539 |
|
|
2023
Q1 | $20.8K | Buy |
825
+12
| +1% | +$302 | ﹤0.01% | 5664 |
|
|
2022
Q4 | $20.3K | Sell |
813
-2
| -0.2% | -$51 | ﹤0.01% | 5699 |
|
|
2022
Q3 | $22K | Sell |
815
-497
| -38% | -$15.8K | ﹤0.01% | 5917 |
|
|
2022
Q2 | $43K | Buy |
1,312
+207
| +19% | +$6.58K | ﹤0.01% | 6057 |
|
|
2022
Q1 | $40K | Sell |
1,105
-2,305
| -68% | -$87.2K | ﹤0.01% | 6305 |
|
|
2021
Q4 | $182K | Buy |
3,410
+2,889
| +555% | +$194K | ﹤0.01% | 5941 |
|
|
2021
Q3 | $39K | Sell |
521
-995
| -66% | -$551K | ﹤0.01% | 6092 |
|
|
2021
Q2 | $1.27M | Buy |
1,516
+193
| +15% | +$174K | ﹤0.01% | 4583 |
|
|
2021
Q1 | $1.13M | Buy |
+1,323
| New | +$1.08M | ﹤0.01% | 4505 |
|
|
2020
Q1 | – | Sell |
-131
| Closed | -$26K | – | 5306 |
|
|
2019
Q4 | $26K | Buy |
131
+69
| +111% | +$15.6K | ﹤0.01% | 5162 |
|
|
2019
Q3 | $15K | Buy |
62
+32
| +107% | +$48.6K | ﹤0.01% | 5116 |
|
|
2019
Q2 | $74K | Sell |
30
-126
| -81% | -$374K | ﹤0.01% | 4976 |
|
|
2019
Q1 | $636K | Buy |
156
+30
| +24% | +$116K | ﹤0.01% | 4299 |
|
|
2018
Q4 | $387K | Buy |
126
+65
| +107% | +$280K | ﹤0.01% | 4508 |
|
|
2018
Q3 | $356K | Sell |
61
-6
| -9% | -$22.8K | ﹤0.01% | 4610 |
|
|
2018
Q2 | $235K | Buy |
67
+32
| +91% | +$117K | ﹤0.01% | 4918 |
|
|
2018
Q1 | $157K | Buy |
35
+3
| +9% | +$13.9K | ﹤0.01% | 5118 |
|
|
2017
Q4 | $122K | Buy |
+32
| New | +$128K | ﹤0.01% | 5669 |
|
|
2017
Q3 | – | Sell |
-81
| Closed | -$366K | – | 6710 |
|
|
2017
Q2 | $366K | Buy |
+81
| New | +$456K | ﹤0.01% | 5340 |
|
Other funds holding FBRX
AAA
MB
Goldman Sachs's FBRX Position: Q2 2026 in Review
Goldman Sachs reduced its Forte Biosciences (FBRX) stake by 25% in Q2 2026, selling an estimated $316K and leaving 40,160 shares worth $853K. The position accounts for ﹤0.01% of the portfolio, ranked #5353.
Goldman Sachs first reported a position in FBRX in Q2 2017 and has held it in 27 quarters since. The position peaked at $1.85M in Q4 2025. 86 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.
- Goldman Sachs held 40,160 shares of Forte Biosciences worth $853K as of Q2 2026.
- Goldman Sachs sold 13,313 Forte Biosciences shares in Q2 2026, an estimated $316K.
- Forte Biosciences made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5353 holding.
- Goldman Sachs first reported a position in Forte Biosciences in Q2 2017 and has held it in 27 quarters since.
- Goldman Sachs's Forte Biosciences position peaked at $1.85M in Q4 2025.
- 86 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.
Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.